2008 financial Highlights

Years ended October 31 (millions of U.S. dollars, except EPS)		2008			2007		% Change
FINANCIAL RESULTS1					(Restated)
Net revenue
MDS Analytical Technologies	$	437		$	352		24%
MDS Nordion	$	296		$	290		2%
MDS Pharma Services	$	482		$	477		1%
	$	1,215		$	1,119		9%
Adjusted EBITDA2	$	151		$	145		4%
Operating loss	$	(693	)	$	(108	)	(542%	)
EPS
Adjusted2	$	0.21		$	0.43		(51%	)
As reported	$	(4.54	)	$	(0.19	)	n/m
Cash from continuing operating activities	$	(18	)	$	176		n/m
Capital expenditures	$	52		$	71		(27%	)
FINANCIAL POSITION
Cash, cash equivalents and short-term investments	$	120		$	324		(63%	)
Total assets	$	1,872		$	3,243		(42%	)
Net debt	$	149		$	47		217%
Shareholders’ equity	$	1,090		$	1,941		(44%	)

1 From continuing operations, except where noted 2 Excluding certain adjusting items as discussed in our MD&A

Over the past three years, our net revenues have grown at a compound annual growth rate of 13%, due primarily to the acquisition of Molecular Devices.